Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

NCT05833867 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Localized Muscle Invasive Bladder Urothelial Carcinoma
Muscle-Invasive Bladder Carcinoma

Interventions

DRUG: Sacituzumab govitecan
RADIATION: Adaptive Radiotherapy

Sponsor

Shilpa Gupta, MD

Collaborators

[object Object]
[object Object]